Published on May 5, 2012 at 5:13 AM
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it will be
presenting clinical data on its lead compounds, tavaborole and AN2728,
at the following upcoming medical meetings:
“Safety and Efficacy of AN2728 and AN2898 Ointments in a Phase 2a
Bilateral Study of Mild-to-Moderate Atopic Dermatitis”
-
72nd Society for Investigative Dermatology Annual Meeting - Thursday,
May 10, 2012
-
"Safety and Efficacy of AN2728 and AN2898 Ointments in a Phase 2a
Bilateral Study of Mild-to-Moderate Atopic Dermatitis"
-
9th Australasian Society for Dermatology Research Conference -
Tuesday, May 22, 2012
-
"Boron-based AN2728 and AN2898 Ointments Demonstrate Safety and
Efficacy in a Phase 2a Bilateral Study of Mild-to-Moderate Atopic
Dermatitis"
-
American Podiatric Medical Association 2012 Annual Scientific Meeting
- The National - Friday, August 17, 2012
-
"Safety and Efficacy of Tavaborole (Formerly AN2690), a Novel
Boron-Based Molecule, in Phase 2 Trials for the Topical Treatment
of Toenail Onychomycosis"
-
American Academy of Dermatology Summer Academy Meeting - Saturday
August 18, 2012
-
"Local Tolerability of AN2728 Topical Ointment, 2% in Sensitive
Skin Areas"
Source: Anacor Pharmaceuticals